Skip to main content

Table 1 Summary of clinical and neuropathological features of control (healthy), C9-ALS and sporadic (non-C9) ALS patient post-mortem brain tissues used in this study

From: RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3

Case ID Gender Race Age at death Age at onset Duration of disease after diagnosis (years) Primary onset Clinical diagnosis Primary neuropathology diagnosis Additional neuropathology diagnoses
CW01-97 F W 57 N/A N/A N/A Normal* Metastatic lung carcinoma 1. Primary age-related Tauopathy; 2. Mild acute ischemic injury, hippocampus
CW01-98 M W 76 N/A N/A N/A Normal* Alzheimer’s disease neuropathologic change, intermediate level Remote frontal lobe infarct
CW99-100 M W 54 N/A N/A N/A Normal* No pathologic changes  
CW03-130 M W   Not available Not available Not available ALS ALS (C9orf72 pattern)  
CW07-94 F W 63 59 4 Hand weakness ALS ALS (C9orf72 pattern) Alzheimer’s disease neuropathologic change, low level
CW07-96 M W 67 Not available Not available Not available ALS ALS (C9orf72 pattern) Alzheimer’s disease neuropathologic change, low level
CW13-97 F W 62 58 4 Leg weakness ALS ALS and FTLD-TDP (C9orf72 pattern) Alzheimer’s disease neuropathologic change, low level
CW98-96 M W 43 42 1 Not available ALS ALS (C9orf72 pattern)  
CW98-97 F W 51 49 2 Not available ALS ALS (C9orf72 pattern)  
CW12-96   Unknown 59 57 1.7 Leg weakness ALS ALS Alzheimer’s disease neuropathologic change, low level
CW15-99 F W 51 46 5 Leg weakness ALS ALS Alzheimer’s disease neuropathologic change, low level
CW12-97 M W 58 58 0.6 Dysarthria ALS ALS Primary age-related tauopathy
  1. M male, F female, W white, N/A not applicable
  2. *Negative for dementia or movement disorders
\